Hepatitis C Virus
InterMune Updates Expense Forecasts and Development Plans
Published in Hepatitis Weekly, April 2nd, 2007
InterMune, Inc. (NASDAQ:ITMN) announced that it has completed a review of its research and development programs and infrastructure requirements. InterMune will implement a number of operational and infrastructure changes that, when fully implemented by 2008, are expected to reduce annual operating expenses by approximately $40 to $50 million. The expense savings result from: 1) a reduction in staffing levels by 50%, or 116 full-time and contract positions affecting all departments; 2) a reduction of development, clinical and regulatory costs due to the termination of the INSPIRE trial; and 3) a reduction of SG&A expenses related to Actimmune(R).
Regarding its...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-04-02)
More Articles from Hepatitis Weekly
- Hepatitis A Virus
The American Liver Foundation Urges Cautious Optimism about CDC Report on Declining Acute Hepatitis Infection Rates - Hepatitis B Virus
Cepheid Introduces CE Mark Certified Smart HBV Test for SmartCycler System - Hepatitis C Virus
Intarcia Raises $50 Million in a Series BB Financing - Hepatitis C Virus
The NHI Drug Reimbursement Price Listing and Launch of the Antiviral Agent "Copegus Tablet 200 mg" for the Treatment of Chronic Hepatitis C - Hepatitis C Virus
Valeant Pharmaceuticals Initiates Taribavirin Phase 2b Clinical Study - Cancer Gene Therapy
Scientists at Shandong University, Institute of Immunology describe research in cancer gene therapy - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
